Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004033 · ClinicalTrials.gov registry record · Phase 2
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
A Phase 2 study of Malignant Mesothelioma, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00004033 is a Phase 2 study of Malignant Mesothelioma that has completed, run by NYU Langone Health. The registered enrollment target is 30 participants, below the 73-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (59% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00004033, a Phase 2 study of Malignant Mesothelioma, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
Conditions Studied
Interventions
- DRUG liposomal NDDP
- PROCEDURE therapeutic thoracoscopy
Study Locations (2)
New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
Texas
- University of Texas - MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1998-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004033
The ClinicalTrials.gov registry entry for NCT00004033 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 73-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target (59% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which liposomal NDDP is the first listed.
NCT00004033 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00004033 about?
NCT00004033 is a clinical study titled "Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma". RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
What is the current status of trial NCT00004033?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1998-09.
What conditions does trial NCT00004033 study?
This clinical trial studies the following conditions: Malignant Mesothelioma.
What interventions are being tested in trial NCT00004033?
The interventions under investigation include: liposomal NDDP (DRUG), therapeutic thoracoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT00004033?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004033 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
RECRUITING · Phase 2
-
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
COMPLETED · Phase 2
-
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
COMPLETED · Phase 2
-
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
COMPLETED · Phase 2
-
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.